6 terminated, 4 active not recruiting, 3 unknown, 2 completed. 12 Phase 2, 5 Phase 1, 2 Phase 3, 1 Not applicable.
Follow oregovomab: new trials by email Literature Review of oregovomab trials Research Report on oregovomab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Oregovomab, Paclitaxel, Carboplatin - Ovarian Neoplasm Epithelial, Ovarian Cancer | Phase 2 | Active not recruiting | CanariaBio Inc. | 88 | 2023-02-07 | 2026-10-23 |
| A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. Oregovomab, Niraparib - Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary | Phase 2 | Active not recruiting | CanariaBio Inc. | 10 | 2022-07-25 | 2026-04-03 |
| Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer Oregovomab, Bevacizumab, Paclitaxel - Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III | Phase 1 / Phase 2 | Active not recruiting | CanariaBio Inc. | 54 | 2021-03-17 | 2026-04-06 |
| Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin Oregovomab, Nivolumab, Chemotherapy - Epithelial Ovarian Cancer | Phase 1 / Phase 2 | Unknown | National Cancer Centre, Singapore | 31 | 2020-10-07 | 2021-12-01 |
| Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery Oregovomab, Paclitaxel, Carboplatin - Carcinoma, Ovarian Epithelial, Ovarian Neoplasms | Phase 3 | Active not recruiting | CanariaBio Inc. | 615 | 2020-08-25 | 2026-04-01 |
| The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer Oregovomab, Poly ICLC - Cancer of Ovary, Neoplasms, Ovarian | Phase 1 | Terminated | CanariaBio Inc. | 10 | 2017-05-30 | 2020-12-22 |
| Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin Nivolumab, Oregovomab - Epithelial Ovarian Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Centre, Singapore | 13 | 2017-02-22 | 2022-06-13 |
| Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer 4-Dimensional Computed Tomography, Fluorouracil, Gemcitabine Hydrochloride - Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma | Phase 2 | Completed | University of Nebraska | 11 | 2013-09-06 | 2023-10-10 |
| A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer Carboplatin, Paclitaxel, oregovomab - Ovarian Neoplasms | Phase 2 | Completed | Quest PharmaTech Inc. | 97 | 2012-06-15 | 2020-09-14 |
| Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy Cyclophosphamide, Laboratory Biomarker Analysis, Oregovomab - Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma | Not applicable | Withdrawn | Gynecologic Oncology Group | 2007-10-01 | 2017-07-14 | |
| Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment oregovomab - Ovarian Cancer | Phase 2 | Terminated | Unither Pharmaceuticals | 40 | 2004-07-01 | 2007-12-18 |
| Clinical Trial for Ovarian Cancer (OvaRex®) oregovomab - Ovarian Cancer | Phase 3 | Terminated | Unither Pharmaceuticals | 354 | 2002-12-01 | 2007-12-18 |
| A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma oregovomab - Ovarian Neoplasms | Phase 1 / Phase 2 | Terminated | Unither Pharmaceuticals | 24 | 2002-03-01 | 2007-12-18 |
| Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma oregovomab - Ovarian Neoplasms | Phase 2 | Terminated | Unither Pharmaceuticals | 102 | 2000-09-01 | 2007-12-18 |
| Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer oregovomab - Fallopian Tube Cancer, Ovarian Cancer | Phase 2 | Unknown | AltaRex | 102 | 1998-11-01 | 2013-11-06 |
| Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy oregovomab - Fallopian Tube Cancer, Ovarian Cancer | Phase 2 | Unknown | AltaRex | 400 | 1998-04-01 | 2013-11-06 |
Ovarian Neoplasms (13) · Carcinoma, Ovarian Epithelial (8) · Fallopian Tube Neoplasms (6) · Adenocarcinoma (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Peritoneal Neoplasms (1)
CanariaBio Inc. (5) · Unither Pharmaceuticals (4) · AltaRex (2) · National Cancer Centre, Singapore (2) · Gynecologic Oncology Group (1) · Quest PharmaTech Inc. (1) · University of Nebraska (1)
United States (11) · Canada (4) · India (2) · Singapore (2) · South Korea (2) · Argentina (1) · Belgium (1) · Brazil (1) · Chile (1) · Czechia (1) · Hungary (1) · Italy (1) · Mexico (1) · Spain (1) · Taiwan (1)
Christopher Nicodemus, MD FACP (2) · Sunil Gupta, MD, FRCPC (2) · Chi Lin (1) · Dr Jung KH, MD (1) · Jack Chan (1) · Jack Chan, MD (1) · Jada Srinivasa Rao, PhD (1) · Jonathan S. Berek, MD (1) · Michael A. Bookman, MD (1) · Robert Edwards (1) · Thomas Woo, M.Sc. (1)
P30CA036727 (1), U10CA027469 (1)